CDT Equity Inc
CDT Equity Inc is a healthcare diagnostics company that provides diagnostic testing and related services to patients and healthcare providers.
Business. CDT Equity Inc (CDT.O) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
CDT Equity Inc (CDT.O) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
CDT Equity Inc has a negative equity position of -$3.1 million and a debt-to-equity ratio of -0.32, indicating a leveraged capital structure with liabilities exceeding assets. The company's liquidity position is rated as medium, with a current ratio of 1.59, suggesting it can cover short-term obligations but with limited buffer. The enterprise value to EBITDA ratio is -3.39, reflecting the company's unprofitable operations and negative cash flows.
Profitability metrics show significant underperformance relative to industry norms. The company reported a net loss of $3.55 million and an operating loss of $2.96 million in the latest period. Return on equity is 1.15%, while return on assets is -0.72%, both well below the industry median for diagnostic companies. The negative operating cash flow of $2.36 million highlights ongoing cash burn that requires close monitoring.
Geographic and segment exposure data is not available in the current dataset, but the company's business model suggests a focus on domestic diagnostic services with potential regional concentration risks. No specific revenue concentration metrics are disclosed, but the negative equity position implies potential overexposure to a single market or customer segment.
The company's growth trajectory is constrained by its current financial position. With a market cap of $9.04 million and negative operating income, CDT lacks the financial capacity for meaningful expansion without external financing. The risk assessment indicates low dilution potential, but the negative net cash position after subtracting total debt suggests potential capital raising needs.
Recent filings and transcripts are not available in the current dataset, but the company's financial statements show consistent operating losses and negative cash flows. The ESG profile reveals a C+ rating with particular weaknesses in the environment pillar, which could impact long-term sustainability.
The company's risk profile is shaped by its unprofitable operations and negative equity position. While dilution risk is currently low, the negative net cash position after debt suggests potential capital raising needs that could increase dilution risk in the future. The ESG controversies score of 100 indicates no current controversies, but the low environment pillar score suggests potential regulatory risks in the healthcare diagnostics sector.
- CDT Equity Inc has a negative equity position of -$3.1 million and a debt-to-equity ratio of -0.32, indicating a leveraged capital structure.
- The company reported a net loss of $3.55 million and an operating loss of $2.96 million in the latest period.
- Return on equity is 1.15%, while return on assets is -0.72%, both well below industry norms for diagnostic companies.
- The company's growth trajectory is constrained by its current financial position and negative operating cash flows.
- The ESG profile reveals a C+ rating with particular weaknesses in the environment pillar, which could impact long-term sustainability.
- The risk assessment indicates low dilution potential, but the negative net cash position after debt suggests potential capital raising needs.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director, Chief Executive Officer · Pre-Funded Warrants → Common StockDisposed 147 401 @ $0,00conversion · 2026-03-24
- 10% owner · Pre-Funded Warrants → Common StockDisposed 51 161 318other · 2026-03-17
- Director · Pre-Funded Warrants → Common StockAcquired 1 940 804 @ $0,00grant · 2026-02-19
- 10% owner · Pre-Funded Warrants → Common StockDisposed 9 968 931other · 2026-02-19
- Director, Chief Executive Officer, 10% owner · Pre-Funded Warrants → Common StockAcquired 3 685 815 @ $0,00grant · 2025-12-08
- Director · Stock Option (Right to Buy) → Common StockAcquired 15 000 @ $1,89grant · 2025-08-05
- Director · Stock Option (Right to Buy) → Common StockAcquired 15 000 @ $1,89grant · 2025-08-05
- Director · Stock Option (Right to Buy) → Common StockAcquired 15 000 @ $1,89grant · 2025-08-05
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Enterprise Valuemarket_cap - net_cash
- CDT Equity Inc Market data — financials · 2026-05-27
- CDT Equity Inc Market data — ESG · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
- 10% owner · Common StockSold 593 289 @ $1,40$829K · 2026-06-18
- 10% owner · Common StockSold 1 464 711 @ $1,44$2,1M · 2026-06-18
- 10% owner · Common StockSold 5 000 @ $0,75$4K · 2026-06-18
- 10% owner · Common StockSold 5 000 @ $0,71$4K · 2026-06-18
- Director, Chief Executive Officer · Common StockOther 100 000 @ $1,90$190K · 2026-05-13
- Director, Chief Executive Officer · Common StockOther 147 401 · 2026-03-24
- 10% owner · Common StockOther 51 420 358 · 2026-03-17
- Director · Common StockOther 10 553 @ $1,04$11K · 2026-02-19
- 10% owner · Common StockOther 46 902 · 2026-02-19
- Director, Chief Executive Officer, 10% owner · Common StockOther 224 800 @ $1,79$402K · 2025-12-08
- Director, CFO · Common StockOther 480 000 · 2025-09-19
- Director, Chief Executive Officer, 10% owner · Common StockOther 1 120 000 @ $0,69$769K · 2025-09-19
- Director · Common StockOther 35 000 · 2025-08-12
- Director · Common StockOther 35 000 · 2025-08-12
- Director · Common StockOther 35 000 · 2025-08-12
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Total assets (YoY) (2025-12-31 vs 2024-12-31): 34.7%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): -1.79xDerived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -5.5%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 49.6%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -138.4%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -60.7%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -120.3%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 98.1%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 98.1%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 172.4%Derived (calculated)
- Return on equity (FY 2025-12-31): 547.1%Derived (calculated)
- Return on assets (FY 2025-12-31): -694.2%Derived (calculated)
- Current ratio (FY 2025-12-31): 0.34xDerived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 16.7%Derived (calculated)
- Total assets (annual): USD 5.65MSEC XBRL filing
- Operating cash flow (annual): USD -15.55MSEC XBRL filing
- Current liabilities (annual): USD 12.82MSEC XBRL filing
- Cash & equivalents (annual): USD 1.51MSEC XBRL filing
- Total operating expenses (annual): USD 36.76MSEC XBRL filing
- Pre-tax income (annual): USD -39.22MSEC XBRL filing
- Net income (annual): USD -39.22MSEC XBRL filing
- R&D expense (annual): USD 5.05MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -1.18KSEC XBRL filing
- Operating income (annual): USD -36.76MSEC XBRL filing